Resource Summary Report

Generated by PRECISE-TBI on Aug 10, 2026

Phospho-Akt (Ser473) (D9E) XP® Rabbit mAb

RRID:AB_2315049
Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 4060, RRID:AB_2315049

Antibody Information

URL: http://antibodyregistry.org/AB_2315049

Proper Citation: Cell Signaling Technology Cat# 4060, RRID:AB_2315049

Target Antigen: Phospho-Akt (Ser473)

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: W, IP, IHC-P, IF-IC, F.
Info: Rated by ISCC, Intestinal Stem Cell Consortium (check ras https://iscc.coh.org/).
Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE
Consolidation on 7/2016: AB_916027, AB_2341228, AB_10234665, AB_916024

Antibody Name: Phospho-Akt (Ser473) (D9E) XP® Rabbit mAb

Description: This recombinant monoclonal targets Phospho-Akt (Ser473)

Target Organism: monkey, rat, hamster, mouse, bovine, zebrafish, human

Clone ID: Clone D9E

Defining Citation: PMID:23749404, PMID:23825125

Antibody ID: AB_2315049

Vendor: Cell Signaling Technology

Catalog Number: 4060

Alternative Catalog Numbers: 4060L, 4060T, 4060S

Record Creation Time: 20250819T222131+0000

Record Last Update: 20250820T015621+0000

Ratings and Alerts

- Rated by ISCC, Intestinal Stem Cell Consortium - ISCC https://iscconsortium.org/resourcecatalog/

No alerts have been found for Phospho-Akt (Ser473) (D9E) XP® Rabbit mAb.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 1295 mentions in open access literature.

Listed below are recent publications. The full list is available at PRECISE-TBI .

Jing J, et al. (2026) Recombinant tissue plasminogen activator protects neurons after intracerebral hemorrhage through activating the PI3K/AKT/mTOR pathway. Neural regeneration research, 21(4), 1574.

Xiong H, et al. (2026) MicroRNA-200s attenuate demyelination caused by Angiostrongylus cantonensis in a mouse model by targeting phosphatase and tensin homolog. Neural regeneration research, 21(6), 2599.

Chen J, et al. (2026) Upregulation of CENPM facilitates glioma progression via PI3K/AKT signaling pathway. Genomics, 118(1), 111163.

Li H, et al. (2026) PDZRN4 suppresses lung adenocarcinoma progression via inhibiting ubiquitin-mediated HIF-1A degradation. Oncogene, 45(4), 577.

Perurena N, et al. (2026) EZH2 Inhibitors Sensitize Breast Cancer to HER2 Kinase Inhibitors through Cooperative Effects on YAP and Proapoptotic Regulators. Cancer research, 86(6), 1467.

Pyun WY, et al. (2026) Nutrient Availability Dictates Cancer Metabolism-Based Therapeutic Responses to Nononcology Drugs. Cancer research, 86(5), 1194.

Zhang Y, et al. (2026) Yinhuo Decoction attenuates depression-like behaviors and promotes M2 microglia polarization by regulating PI3K/Akt/NF-?B signaling pathway in a murine model of menopausal depression. Journal of ethnopharmacology, 363, 121365.

Gonzalez Ramirez ML, et al. (2026) Signaling bias of the protease-activated receptor-1 is dictated by distinct GRK5 and ?-arrestin-2 determinants. Cell reports, 45(3), 117041.

Song J, et al. (2026) Ets1-dependent Mek-Erk signaling drives adipose tissue macrophage anti-inflammatory polarization to ameliorates insulin resistance. Cell reports, 45(4), 117244.

Daniali M, et al. (2026) It's Not Rewarding for Mitochondria: Dopamine-Induced Mitochondrial Dysfunction Activates cGAS-STING to Drive IL-6 Secretion in Macrophages. bioRxiv : the preprint server for biology.

Luo S, et al. (2026) Pan-cancer neurotransmitter receptor alterations define neuroregulatory subtypes with prognostic significance. Cell reports, 45(5), 117340.

Ge X, et al. (2026) PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition. Cancer research, 86(15), 3819.

Meng F, et al. (2026) The UFL1-AKT positive feedback loop promotes breast cancer progression by enhancing lipid synthesis. Nature communications, 17(1), 614.

Shen Y, et al. (2026) CCL1-AMFR Facilitates Glioblastoma Progression by Modulating the Cross-talk between Glioma Cells and Tumor-Associated Macrophages. Cancer immunology research, 14(4), 676.

Xie C, et al. (2026) Lysosome-localized IRTKS condensates promote mTORC1 activity leading to MASLD and HCC. Cell reports, 45(2), 116893.

Govindarajan M, et al. (2026) Pan-cancer N-glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as an actionable surface target. Cell reports. Medicine, 7(2), 102578.

Wetterwald L, et al. (2026) MYCT1-IFITM2/3 interaction links endothelial endolysosomal trafficking to white adipose tissue expansion. The Journal of experimental medicine, 223(5).

Wu X, et al. (2026) Ursodeoxycholic acid inhibits platelet activation and thrombosis via TREM2: Evidence from mouse models and human studies. British journal of pharmacology.

Chien JY, et al. (2026) Nostoc commune Extract Attenuates Oxidative Stress and Neuroinflammation in Ischemic Optic Neuropathy Through PI3K/AKT/mTOR Signaling. Antioxidants (Basel, Switzerland), 15(5).

Goldman A, et al. (2026) An LRRK2 variant blocks NCOA4 trafficking upon iron overload, leading to ferroptotic death. Journal of cell science, 139(14).